PH12020550906A1 - Immunostimulatory oligonucleotides - Google Patents

Immunostimulatory oligonucleotides

Info

Publication number
PH12020550906A1
PH12020550906A1 PH12020550906A PH12020550906A PH12020550906A1 PH 12020550906 A1 PH12020550906 A1 PH 12020550906A1 PH 12020550906 A PH12020550906 A PH 12020550906A PH 12020550906 A PH12020550906 A PH 12020550906A PH 12020550906 A1 PH12020550906 A1 PH 12020550906A1
Authority
PH
Philippines
Prior art keywords
methods
immunostimulatory oligonucleotides
oligonucleotides
immunostimulatory
tlr9
Prior art date
Application number
PH12020550906A
Other languages
English (en)
Inventor
Thomas Ilg
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of PH12020550906A1 publication Critical patent/PH12020550906A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12020550906A 2017-12-15 2020-06-15 Immunostimulatory oligonucleotides PH12020550906A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17207746 2017-12-15
EP17207740 2017-12-15
EP17207750 2017-12-15
PCT/EP2018/084019 WO2019115402A1 (en) 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides

Publications (1)

Publication Number Publication Date
PH12020550906A1 true PH12020550906A1 (en) 2021-05-17

Family

ID=66818991

Family Applications (3)

Application Number Title Priority Date Filing Date
PH12020550906A PH12020550906A1 (en) 2017-12-15 2020-06-15 Immunostimulatory oligonucleotides
PH12020550903A PH12020550903A1 (en) 2017-12-15 2020-06-15 Immunostimulatory compositions
PH12020550904A PH12020550904A1 (en) 2017-12-15 2020-06-15 Immunostimulatory oligonucleotides

Family Applications After (2)

Application Number Title Priority Date Filing Date
PH12020550903A PH12020550903A1 (en) 2017-12-15 2020-06-15 Immunostimulatory compositions
PH12020550904A PH12020550904A1 (en) 2017-12-15 2020-06-15 Immunostimulatory oligonucleotides

Country Status (24)

Country Link
US (7) US20210062192A1 (https=)
EP (4) EP3700564B1 (https=)
JP (5) JP7458977B2 (https=)
KR (4) KR102787688B1 (https=)
CN (5) CN119656298A (https=)
AU (5) AU2018385257B2 (https=)
BR (2) BR112020011815A2 (https=)
CA (3) CA3085575A1 (https=)
CL (3) CL2020001560A1 (https=)
CO (3) CO2020007120A2 (https=)
CR (1) CR20200260A (https=)
DK (1) DK3700564T3 (https=)
DO (3) DOP2020000106A (https=)
ES (1) ES3052969T3 (https=)
IL (3) IL274975A (https=)
MX (4) MX2020006244A (https=)
PE (3) PE20210635A1 (https=)
PH (3) PH12020550906A1 (https=)
PL (1) PL3700564T3 (https=)
SG (3) SG11202004471RA (https=)
TW (3) TWI821224B (https=)
UY (3) UY38016A (https=)
WO (3) WO2019115386A1 (https=)
ZA (1) ZA202004317B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021007160A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
WO2021154745A1 (en) * 2020-01-27 2021-08-05 Oregon State University Gonorrhea subunit vaccine
CN113493790A (zh) 2020-04-01 2021-10-12 南京华普生物技术股份有限公司 具有免疫调节功能的CpG ODN及其应用
EP3892260A1 (en) * 2020-04-10 2021-10-13 Bayer Animal Health GmbH Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids
CN116056765A (zh) 2020-08-07 2023-05-02 坦伯公司 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
CN112159814B (zh) * 2020-10-29 2023-05-16 中国农业科学院兰州兽医研究所 一种CpG寡聚脱氧核苷酸及制备与其用途
CN113797329A (zh) * 2021-10-19 2021-12-17 启锰生物科技(江苏)有限公司 一种二价锰佐剂和CpG佐剂的疫苗佐剂组合物及其制作方法
CN116218852A (zh) * 2023-02-22 2023-06-06 中国人民解放军陆军军医大学 一种靶向基因启动子G-四联体区域的sgRNA及其用途
WO2025149000A1 (zh) * 2024-01-09 2025-07-17 康希诺(上海)生物研发有限公司 一种免疫刺激序列截断多聚a尾的序列构建及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719028A (en) * 1992-12-07 1998-02-17 Third Wave Technologies Inc. Cleavase fragment length polymorphism
EP1167379A3 (en) * 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
NZ517929A (en) 1999-09-25 2004-02-27 Univ Iowa Res Found Immunostimulatory nucleic acids
AU783118B2 (en) * 1999-09-27 2005-09-29 Coley Pharmaceutical Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
KR100359753B1 (ko) * 1999-12-21 2002-11-09 주식회사 제넥신 면역조절능력 및 안전성이 증가되고 ｄＧ 연속서열이결합된 포스포다이에스터 ＣｐＧ올리고데옥시뉴클레오티드 변형체
WO2002002807A2 (en) 2000-06-30 2002-01-10 Epigenomics Ag Diagnosis of diseases associated with cell signalling
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
MXPA05013658A (es) * 2003-06-11 2006-03-02 Hybridon Inc Oligonucleotidos inmunomoduladores estabilizados.
AU2004275876B2 (en) 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
EP1678303A2 (en) * 2003-10-30 2006-07-12 Coley Pharmaceutical GmbH C-class oligonucleotide analogs with enhanced immunostimulatory potency
EP1680446B1 (en) * 2003-11-05 2007-10-31 Pevion Biotech Ltd. Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens
CN1250737C (zh) * 2003-11-07 2006-04-12 深圳市未来海洋科技发展有限公司 含CpG DNA畜禽疫苗佐剂的PCR制备方法
KR100558851B1 (ko) * 2004-01-08 2006-03-10 학교법인연세대학교 면역조절능력이 증가된 ＣｐＧ 올리고데옥시뉴클레오티드변형체
CN1989439B (zh) * 2004-05-06 2010-12-29 美国政府健康及人类服务部 治疗葡萄膜炎的方法以及组合物
US20080009455A9 (en) * 2005-02-24 2008-01-10 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
EP1764108A1 (en) * 2005-09-14 2007-03-21 Gunther Hartmann Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
US8114636B2 (en) * 2006-02-10 2012-02-14 Life Technologies Corporation Labeling and detection of nucleic acids
DK2405002T3 (en) 2006-02-15 2015-01-05 Adiutide Pharmaceuticals Gmbh Compositions and methods for oligonukleotidformuleringer
CN100418583C (zh) * 2006-02-21 2008-09-17 朱鸿飞 预防和治疗乳腺炎的药物组合物
US20080124366A1 (en) 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
CN101240271B (zh) * 2006-08-28 2012-08-29 长春华普生物技术有限公司 Toll样受体调节性寡核苷酸及其用途
PT2078080E (pt) 2006-09-27 2015-09-18 Coley Pharm Gmbh Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
KR20100045508A (ko) 2007-08-13 2010-05-03 콜리 파마슈티칼 게엠베하 특이적 면역 조절 프로필을 유도하는 규정된 뉴클레오티드간 연결의 환경에서의 ｒｎａ 서열 모티프
WO2010129672A1 (en) 2009-05-05 2010-11-11 Miragen Therapeutics Lipophilic polynucleotide conjugates
WO2010130374A1 (en) * 2009-05-14 2010-11-18 Bayer Animal Health Gmbh Enhanced immune response in avian species
EP2575878B1 (en) 2010-05-28 2018-06-13 Zoetis Belgium S.A. Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules
CN101979542B (zh) * 2010-10-28 2011-12-28 国家兽用生物制品工程技术研究中心 含CpG基序的核酸序列的制备方法及应用
BR112013016231B1 (pt) 2010-12-22 2021-03-23 Bayer Intellectual Property Gmbh Composição imunomoduladora para o tratamento de doença respiratória bovina
EP2471926A3 (en) * 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
PL2714908T3 (pl) * 2011-05-26 2018-07-31 Intervet International B.V. Oligodeoksynukleotydy immunostymulacyjne
MX346596B (es) * 2011-05-26 2017-03-23 Intervet Int Bv Oligodesoxinucleotidos inmunoestimuladores.
JP6375289B2 (ja) 2012-04-05 2018-08-15 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
AR091569A1 (es) * 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
WO2014082083A1 (en) * 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
US9506030B2 (en) 2013-05-01 2016-11-29 Regulus Therapeutics Inc. Compounds and methods for enhanced cellular uptake
CN112263675B (zh) * 2013-07-19 2024-02-27 财团法人卫生研究院 CpG寡脱氧核苷酸、包含其的免疫组合物及制备组合物并通过其刺激免疫反应的方法
AR097029A1 (es) * 2013-07-26 2016-02-17 Intervet Int Bv Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
GB2517700A (en) * 2013-08-27 2015-03-04 Lgc Ltd Oligonucleotides comprising a secondary structure and uses thereof
KR20160122849A (ko) 2014-02-28 2016-10-24 바이엘 애니멀 헬스 게엠베하 면역자극성 플라스미드
US10888603B2 (en) * 2016-02-12 2021-01-12 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cancer cells expressing tumor-associated integrins

Also Published As

Publication number Publication date
PH12020550904A1 (en) 2021-05-17
CO2020007102A2 (es) 2020-06-19
JP7273040B2 (ja) 2023-05-12
CR20200260A (es) 2020-08-01
US20210170020A1 (en) 2021-06-10
US20210062192A1 (en) 2021-03-04
JP2021506779A (ja) 2021-02-22
MX2020006246A (es) 2020-09-03
AU2018385257A1 (en) 2020-06-18
CN111447949B (zh) 2025-07-11
US11932857B2 (en) 2024-03-19
KR20250048594A (ko) 2025-04-09
CL2020001560A1 (es) 2020-11-06
US20230332162A1 (en) 2023-10-19
AU2025205082A1 (en) 2025-07-31
US20230174990A1 (en) 2023-06-08
EP3701032A1 (en) 2020-09-02
TW201940192A (zh) 2019-10-16
US11542507B2 (en) 2023-01-03
AU2018382419B2 (en) 2025-04-10
DOP2020000107A (es) 2020-08-31
DOP2020000113A (es) 2020-08-31
SG11202004773SA (en) 2020-06-29
WO2019115402A1 (en) 2019-06-20
BR112020011838A2 (pt) 2020-11-24
KR20200099556A (ko) 2020-08-24
IL275217A (en) 2020-07-30
IL274975A (en) 2020-07-30
CN111801419A (zh) 2020-10-20
CO2020007100A2 (es) 2020-06-19
TWI911138B (zh) 2026-01-11
TW201936924A (zh) 2019-09-16
SG11202004952UA (en) 2020-06-29
KR20200098637A (ko) 2020-08-20
BR112020011815A2 (pt) 2020-11-17
PE20210636A1 (es) 2021-03-23
UY38014A (es) 2019-06-28
JP7760560B2 (ja) 2025-10-27
MX2020006243A (es) 2020-09-03
RU2020122545A3 (https=) 2022-05-04
CO2020007120A2 (es) 2020-06-19
WO2019115386A9 (en) 2020-07-23
CL2020001562A1 (es) 2020-11-06
PE20200933A1 (es) 2020-09-17
EP3694549A1 (en) 2020-08-19
RU2020122553A (ru) 2022-01-17
CN111801116A (zh) 2020-10-20
EP4647437A3 (en) 2026-02-18
AU2018385256A1 (en) 2020-06-11
MX2025007909A (es) 2025-08-01
AU2018385257B2 (en) 2025-04-10
KR20200098638A (ko) 2020-08-20
CN120519464A (zh) 2025-08-22
JP2021506246A (ja) 2021-02-22
JP2021506245A (ja) 2021-02-22
US12305173B2 (en) 2025-05-20
DOP2020000106A (es) 2020-08-31
TWI821224B (zh) 2023-11-11
PE20210635A1 (es) 2021-03-23
CA3085657A1 (en) 2019-06-20
TW201936923A (zh) 2019-09-16
US20250215439A1 (en) 2025-07-03
RU2020122545A (ru) 2022-01-19
JP7770769B2 (ja) 2025-11-17
ES3052969T3 (en) 2026-01-16
DK3700564T3 (da) 2025-11-10
CA3085575A1 (en) 2019-06-20
KR102787688B1 (ko) 2025-03-27
US20200385733A1 (en) 2020-12-10
EP4647437A2 (en) 2025-11-12
JP7458977B2 (ja) 2024-04-01
CL2020001561A1 (es) 2020-11-06
EP3700564A1 (en) 2020-09-02
JP2023156485A (ja) 2023-10-24
WO2019115385A1 (en) 2019-06-20
AU2018382419A1 (en) 2020-06-04
AU2025204678A1 (en) 2025-07-17
ZA202004317B (en) 2023-05-31
MX2020006244A (es) 2020-09-03
AU2018385256B2 (en) 2025-09-25
CN119656298A (zh) 2025-03-21
US20240076681A1 (en) 2024-03-07
IL275086A (en) 2020-07-30
JP2023153970A (ja) 2023-10-18
TWI900461B (zh) 2025-10-11
SG11202004471RA (en) 2020-06-29
CN111447949A (zh) 2020-07-24
PL3700564T3 (pl) 2026-02-23
EP3700564B1 (en) 2025-09-17
CA3085661A1 (en) 2019-06-20
UY38015A (es) 2019-06-28
WO2019115386A1 (en) 2019-06-20
BR112020011845A2 (pt) 2020-11-24
UY38016A (es) 2019-06-28
CN111801116B (zh) 2024-11-26
PH12020550903A1 (en) 2021-05-17

Similar Documents

Publication Publication Date Title
PH12020550906A1 (en) Immunostimulatory oligonucleotides
MX2022011934A (es) Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
PH12019500193A1 (en) Chimeric antigen receptors targeting bcma and methods of use thereof
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
EP3536168A3 (en) Probiotic formulations and methods for use
MX421186B (es) Constructos de anticuerpos.
MX2020004600A (es) Constructos de oligonucleotidos y usos de estos.
MX2011008067A (es) Novedosos agonistas sinteticos del receptor 9 tipo toll.
HK1250637A1 (zh) 用於引发免疫应答的剂和组合物
WO2016179034A3 (en) Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
PH12018501170A1 (en) Vaccination with mica/b alpha 3 domain for the treatment of cancer
JOP20190164A1 (ar) تركيبات وطرق لعلاج داء فاربر
EP4241786A3 (en) Methods and compositions for stimulating immune response
CR20200262A (es) Oligonucleótidos inmunoestimulantes
SG11202106494RA (en) Compositions, methods and uses for eliciting an immune response
WO2019186514A3 (en) Aptamers for targeted activaton of t cell-mediated immunity
TH2001003350A (th) โอลิโกนิวคลีโอไทด์ที่กระตุ้นระบบภูมิคุ้มกัน
AR113949A1 (es) Oligonucleótidos inmunoestimulantes
ZA201905875B (en) Immunostimulating compositions and uses therefore
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.
TH2001003352A (th) โอลิโกนิวคลีโอไทด์ที่กระตุ้นภูมิคุ้มกัน
HK40087478A (en) Immunogenic constructs, compositions, and methods for inducing immune response
AR113950A1 (es) Composiciones inmunoestimulantes
PL412612A1 (pl) Szczep Gram-dodatniej laseczki Bacillus subtillis, rekombinowane przetrwalniki, kompozycja immunogenna, doustna szczepionka oraz jej zastosowanie przeciwko wirusowi grypy typu A